SCHEMBL23925887

SCHEMBL23925887

Oc1cc(Oc2cccc(-c3cccs3)n2)ccc1F

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B14 Q9BPX1 4/20 0.62
MAPT P10636 5/20 0.46
KDM4E B2RXH2 5/20 0.46
ALDH1A1 P00352 5/20 0.46
HPGD P15428 3/20 0.46
TDP1 Q9NUW8 3/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
SMN1; SMN2 Q16637 5/20 0.39
NPC1 O15118 3/20 0.39
RPS6KB2 Q9UBS0 1/20 0.38
RAB9A P51151 4/20 0.36
RXFP1 Q9HBX9 3/20 0.36
PPARG P37231 1/20 0.36
NCOA2 Q15596 1/20 0.36
NCOA1 Q15788 1/20 0.36
NCOA3 Q9Y6Q9 1/20 0.36
ERN1 O75460 1/20 0.35
CYP1A2 P05177 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30510820 0.80 HSD17B14 (0.70) HSD17B14MAPTALDH1A1HPGDHSD17B10
SCHEMBL23943430 0.80 HSD17B14 (0.70) HSD17B14MAPTHSD17B1HSD17B2
SCHEMBL30510802 0.80 HSD17B14 (0.70) HSD17B14MAPTHSD17B1HSD17B2
SCHEMBL23943385 0.80 HSD17B14 (0.70) HSD17B14MAPTALDH1A1HPGDHSD17B10
SCHEMBL23943317 0.80 HSD17B14 (0.59) HSD17B14ERN1HSD17B1HSD17B2
SCHEMBL30510812 0.80 HSD17B14 (0.59) HSD17B14ERN1HSD17B1HSD17B2
SCHEMBL23943410 0.78 HSD17B14 (0.67) HSD17B14HSD17B1HSD17B2
SCHEMBL23943405 0.78 HSD17B14 (0.67) HSD17B14HSD17B1HSD17B2
SCHEMBL23943390 0.78 HSD17B14 (0.79) HSD17B14HSD17B1HSD17B2
SCHEMBL23943408 0.78 HSD17B14 (0.79) HSD17B14MAPTALDH1A1L3MBTL1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230150940-A1 HSD17B13 INHIBITORS AND USES THEREOF INIPHARM, INC. 2023-05-18 US disclosed
US-20230150940-A1 HSD17B13 INHIBITORS AND USES THEREOF INIPHARM, INC. 2023-05-18 US disclosed
US-20230150940-A1 HSD17B13 INHIBITORS AND USES THEREOF INIPHARM, INC. 2023-05-18 US disclosed
WO-2021211974-A1 HSD17B13 INHIBITORS AND USES THEREOF INIPHARM, INC. (US) 2021-10-21 WO disclosed
WO-2021211974-A1 HSD17B13 INHIBITORS AND USES THEREOF INIPHARM, INC. (US) 2021-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230150940-A1 HSD17B13 INHIBITORS AND USES THEREOF HSD17B1, HSD17B3, HSD17B13 HSD17B14 7/4885MAPT 2620/4885KDM4E 3882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.